COGNO and ABCARA are delighted to announce the launch of the OPAL study – a national, multi-site Phase 1 clinical trial of CT-179, a first-in-class orally bioavailable brain penetrant small molecule targeting OLIG2, a key protein associated with glioblastoma cancer stem cells.
